Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis

Study identifier:ALXN1210-MG-306

ClinicalTrials.gov identifier:NCT03920293

EudraCT identifier:2018-003243-39

CTIS identifier:N/A

Study Complete

Official Title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis

Medical condition

Generalized Myasthenia Gravis

Phase

Phase 3

Healthy volunteers

No

Study drug

Placebo

Sex

All

Actual Enrollment

175

Study type

Interventional

Age

n/a - n/a

Date

Study Start Date: 12 Mar 2019
Primary Completion Date: 11 May 2021
Study Completion Date: 25 May 2023

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Apr 2024 by Alexion Pharmaceuticals, Inc.

Sponsors

Alexion Pharmaceuticals, Inc.

Collaborators

-

Inclusion and exclusion criteria